DNAP Over on RB:
ragingbull.altavista.com
DNAP IN BARRONS PAGE 52 !!!!!!!!!!!!!!!!!!!!!
(SEPT 25 issue)
ragingbull.altavista.com
Barrons:
DNAprint. genomics: (DNAP pink sheets) dnaprint.com
The recently announced completion of the human genome sequence has opened the
gates for a new style of medical research that will lead to a personalization or
customization of medicine. Personalized medical practice in the future will match patients
with prescription drugs in order to maximize efficacy and minimize contraindication (side
effects). To do this, clinics of the future will read genetic data from their patients saliva
and/or blood, and screen this “read” against “solutions” generated by genomics
companies.
DNAprint genomics intends to be the first to establish a portfolio of these “diagnomics
solutions”, as well as the tools for their use. The company was founded by a group of
scientists with research and commercial experience in high-level mathematical modeling,
programming and molecular genetics. The company’s software and information products
will provide practitioners of personalized medicine with a comprehensive system for
patient classification. Health care professionals and biopharmaceutical scientists will be
able to use the company’s system, through a combination of on-site hardware/software
placement and ASP (application-service provider) resources, to draw highly
sophisticated conclusions and associations between genotype (SNP and haplotype)
data and phenotypic traits (such as drug response or disease). The analytical heart of the
system is a collection of sophisticated algorithms that enable a quantitative and
multivariate dissection of high-density genotype matrices in complex genetic terms for
various human diseases and drug-interaction traits. The system uses a variety of novel
mathematical modeling and programming techniques. The company is applying it’s
informatics platform to real-world pharmacogenomic study in order to build a portfolio of
clinical “solutions” that mathematically express the nature of the genotype-phenotype
relationship for a given drug. (Each “solution” will be used by DNAprint genomics
customers as a template against which they can screen clinical unknowns through the
companies ASP.)
In addition to DNAPrints unprecedented analytical power within the field of human genetic
variation, the company is establishing a one-of-a-kind knowledge resource to which this
power will be applied. In order to develop diagnomics solutions, massive amounts of
genetic data are required to serve as a “road map” upon which discovery and
development routines can be based. For any genomics company, intellectual property
and proprietary genetic information is the foundation for future success. DNAPrint has
engineered proprietary automated software, reagents and protocols to develop a
pipeline of proprietary genetic data flow to own proprietary data warehouse (the
DNAPrint PHENOMESM database). This pipeline system extracts information from the
newly available public human genome database. However, most companies who rely on
this resource are at a disadvantage, because it was built from a small numbers of healthy
human donors and is therefore biased against information with value for application to
the study of specific human problems. Because of this the company has constructed and
uses its pipeline system to mine data from its own proprietary gene database as well.
Since this gene database is derived from large target populations that exhibit certain
genetic traits, the company enjoys the use of private knowledge base with an
unprecedented degree of information content for application to personalized medicine
research. Thus, in addition to its proprietary mathematical modeling and algorithmic
capabilities for the use of genetic “road maps” in general, the company also possesses a
unique genetic “road map” that confers to the company a distinct advantage for the
discovery and development of diagnomics products for tomorrows personalized
medicine.
Accomplishments within the first few months of operation include the development of two
automated software systems for the discovery of genetic variation, the provisional
patenting of a unique biochemical reagent useful for high-throughput genetic analysis, the
development and peer-reviewed publication of novel mathematical concepts useful for
finding genetic patterns from high-density genotype data sets, and the inking of the
companies first strategic alliance. In addition, the company is in the late stages of
negotiating alliances with several high profile organizations which promise to yield
access to high-value biological and hardware resources, and DNAPrint’s lead scientists
have been invited to present at two prestigious genomics conferences later this year.
WALL STREET REPORTER INTEVIEW WITH CEO- Tony Frudakis, Ph.D.,
President/Chief Scientific Officer/CEO
DNAprint genomics, Inc.
(OTC: DNAP)-----
Investor Inquiries
DNAprint genomics Inc.
Richard Craig Hall,
941/341-0136
ragingbull.altavista.com
Tru_pikture/All:
"Interesting that a Pink Sheet stock has an article in Barron's..."
Very true tru_pikture, but, did the rest of you take the time to actually read the article?
Notice the word- proprietary:
However, most companies who rely on this resource are at a disadvantage, because it was built from a small numbers of healthy human donors and is therefore biased against information with value for application to the study of specific human problems. Because of this the company has constructed and uses its pipeline system to mine data from its own proprietary gene database as well. Since this gene database is derived from large target populations that exhibit certain genetic traits, the company enjoys the use of private knowledge base with an unprecedented degree of information content for application to personalized medicine research.
Thus, in addition to its proprietary mathematical modeling and algorithmic capabilities for the use of genetic “road maps” in general, the company also possesses a unique
genetic “road map” that confers to the company a distinct advantage for the discovery and development of diagnomics products for tomorrows personalized medicine.
Did y'all pay attention to this as well?:
Accomplishments within the first few months of operation include... and the inking of the companies first strategic alliance. In addition, the company is in the late stages of negotiating alliances with several high profile organizations which promise to yield access to high-value biological and hardware resources,...
Not bad for a "pink" company IMHO...
Theo;-) |
